Some of its effects, like blood sugar changes, digestive discomfort, and hormone fluctuations, could lead to irritability
Zhang W, Joseph E, Hitchcock C, DiSilvestro RA
Impurities, incorrect peptide sequences, or degraded stock significantly affect experimental outcomes
With all doses now listed as available, the FDA may soon pull it off the list, depending on its conversations with Novo about whether the company can sufficiently meet demand going forward
1 The results suggested an association between semaglutide use and an increased risk of NAION in patients with type 2 diabetes or obesity, though future research is needed to establish causality